HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA OTC labeling rule crowds out "important consumer information" -- CTFA.

This article was originally published in The Rose Sheet

Executive Summary

FDA OTC LABEL RULE WOULD EXCLUDE "IMPORTANT CONSUMER INFORMATION," CTFA said, including claims such as non-comedo-genic, PABA free and fragrance free. Addressing FDA's Nonprescription Drugs Advisory Committee on the issue of FDA's proposed OTC label reform rule July 14, Cosmetic, Toiletry & Fragrance Association Assistant General Counsel Stephen Gettings maintained that "other important consumer information that's not required by any government agency," but is included on cosmetics packaging, is not accounted for under FDA's proposed labeling reg. These claims would be crowded out of labeling due to the amount of information required within a rigid template under the agency's proposal, CTFA asserted.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel